Abstracts A141 patients. Adherent patients had lower rate of depression (4.7% vs. 9.5%, P = 0.019), higher rate of previous DMD use (49.1% vs. 40.0%, P = 0.032), and higher baseline MS-related costs ($4757 vs. $4037, P < 0.001). After adjusting for differences in baseline characteristics, DMD adherent patients had lower occurrence of severe relapses (12.4% vs. 19.9%, P = 0.013) and lower total (direct and indirect) costs ($14,095 vs. $16,638, P = 0.048). CONCLUSIONS: Over the two-year study period, DMD adherence was associated with significantly fewer severe relapses and lower total medical costs. OBJECTIVES: To assess the contribution of the Zarit score, a measure of perceived caregiver burden in Alzheimer's disease, to health related quality of life as measured by the physical and mental component scores of the SF-12 instrument and SF-6D health utilities. METHODS: A survey of Alzheimer caregivers was undertaken in the US in 2009 (n = 1,079). This survey captured both the characteristics of caregivers and the characteristics of the patient to whom the caregiver gave most attention. At the same time, caregivers were asked to complete the Zarit burden of care questionnaire and the SF-12 HRQoL instrument. To assess the impact of Zarit scores on HRQoL, linear regression (ordinary least squares) models were specified and estimated for the physical and mental component summary scores of the SF-12 and the health utility scores from the SF-6D. Independent variables included: caregiver and patient characteristics. RESULTS: Average PCS and MCS scores were 47.7 (STD 11.17) and 42.5 (STD 11.93) respectively; utility score was 0.68 (STD 0.13). Zarit scores were distributed with 20.4% of respondents reporting a minimal or no burden, 37.7% a mild to moderate burden, 33.1% moderate to severe burden and 8.8% a severe burden. Overall16.3% were judged to have mild AD, 53.7% moderate and 30.0% severe. Zarit scores played the key role with their greatest impact on the MCS rather than the PCS dimensions of the SF-12. In the severe AD category the PCS deficit is −5.65 (t = −4.23) compared to a deficit of −17.94 (t = −14.09) for MCS. The corresponding health utility deficit is −0.19 (t = −13.15). Other key variables are caregiver age and gender, patient age and gender and living situation. CONCLUSIONS: Perceived caregiver burden is associated primarily with deficits on the mental component scores of the SF-12 and on SF-6D health utilities. OBJECTIVES: Bladder dysfunction is a common symptom in patients with multiple sclerosis (MS). This study assessed the current literature regarding instruments that have been used to measure the health-related quality of life (HRQOL) impact of this chronic illness, and to what extent bladder dysfunction affects HRQOL in this population. METHODS: Two searches using MEDLINE/PubMed's MeSH database were made. Quality of life was isolated by checking the psychology subheading within the
McGill University, Montreal, QC, Canada OBJECTIVES: Botulinum Toxin Type-A (BoNTA) is approved for many therapeutic indications in Canada, including blepharospasm, 7th cranial nerve disorders, cervical dystonia, focal spasticity, cerebral palsy, and hyperhidrosis. Unfortunately, little is known about the impact of treatment on health utility. The objective of the ongoing national MOBILITY study is to measure the impact of BoNTA on health utility. METHODS: Phase IV prospective observational cohort study in patients receiving BoNTA for approved therapeutic indications in Canada. Physical component scores (PCS), and mental component scores (MCS) are derived from self-reported SF-12v2 at baseline, week 4 and subsequent clinic visits. Health utility is then measured using the SF-6D scoring programme. In this interim analysis continuous data were analyzed by student's t-test and dichotomous data by Chi-square test. RESULTS: To date 917 patients have been enrolled at 40 clinical sites with a 94.5% retention rate. 69.7% of patients returned the week 4 survey and data from 608 individuals were included in the analysis (526 were receiving ongoing BOTOX® treatment at baseline; 82 were BoNTA-naïve). Significant differences were detected in self-reported SF-6D scores between baseline and week 4 in the analysis of continuous (p = 0.05) and dichotomized data (p = 0.0001), and between baseline and week 4 in the analysis of continuous MCS data (p = 0.03). Among BoNTA-naïve patients, there was a statistically significant difference in SF-6D scores between baseline and week 4 (p = 0.03 for continuous data; p = 0.018 for dichotomized data). There were no statistical significant changes in the SF-6D scores for patients receiving on-going treatment. CONCLUSIONS: This interim analysis from a large ongoing national study shows that significant improvements in health utility are obtained in patients receiving BoNTA for therapeutic indications. Health utility benefit was most pronounced in BoNTA-naive patients as evidenced by week 4 MCS scores (the expected peak effect window). Further recruitment and long term follow-up and analyses are ongoing.
PND22 MAPPING FROM DISEASE-SPECIFIC MEASURES TO HEALTH-STATE UTILITY VALUES IN CHRONIC MIGRAINEURS
Gillard PJ 1 , Devine B 1 , Varon SF 2 , Maglinte GA 2 , Sullivan S 1 1 University of Washington, Department of Pharmacy, Seattle, WA, USA, 2 Allergan, Inc, Irvine, CA, USA OBJECTIVES: To develop algorithms that convert disease-specific quality-of-life scores for the Headache Impact Test (HIT)-6 and the Migraine Specific Quality of Life, v. 2.1 (MSQ) Questionnaire to health-state utility values derived from the EuroQoL-5D (EQ-5D) in chronic migraineurs. METHODS: Data from a cross-sectional multi-country study was used. Chronic migraineurs (ICHD-2 diagnosis of migraine and ≥15 headache days/month) completed a series of questions including the HIT-6 (n = 547), MSQ (n = 499), and EQ-5D. Subjects were randomly assigned to training and validation samples of equal size. Correlations between paired EQ-5D index scores and both HIT-6 scores and MSQ domain scores (Role-Restrictive [RR], Role-Preventative [RP], and Emotional-Function [EF]) were examined using Spearman correlation coefficients. Regression models were constructed to predict EQ-5D utility values from the HIT-6 scores or the MSQ domain scores. Preferred algorithms were validated using the validation samples. RESULTS: Correlations between the EQ-5D index score and the HIT-6 and MSQ dimension scores were statistically significant (p < 0.001) with correlation coefficients of −0.33 (HIT-6), 0.44 (MSQ-RR), 0.46 (MSQ-RP), and 0.30 (MSQ-EF). The preferred HIT-6 algorithm was a non-linear model which contained a quadratic term for HIT-6, and explained 34% of the variance in the training sample. The preferred MSQ algorithm was a linear model with covariates representing each domain, and explained 43% of the variance in the training sample. Both models also included covariates for age, gender, employment status, headache medication use, and comorbidities. In the validation analyses, no statistically significant difference was observed between the mean observed EQ-5D score and the mean EQ-5D score estimated using the preferred algorithms. CONCLUSIONS: The relationship between the two disease-specific instruments and the EQ-5D are sufficiently robust to use regression equations to estimate EQ-5D utility values. These preferred models may be useful in estimating health-state utilities in trials of CM patients where no preference-based measure is present.
PND23

CONCORDANCE OF SELF-REPORT MEASURES OF DSM-IV-TR, ICD-10, AND RDC INSOMNIA WITH STANDARDIZED CLINICAL ASSESSMENTS IN THE AMERICA INSOMNIA SURVEY (AIS)
Kessler RC 1 , Coulouvrat C 2 , Lakoma MD 1 , Hajak G 3 , Roth T 4 , Sampson N 1 , Shahly V 1 , Shillington AC 5 , Stephenson JJ 6 , Walsh J 7 , Zammit G 8 1 Harvard Medical School, Boston, MA, USA, 2 Sanofi-Aventis Group, Paris, France, 3 University of Regensburg, Regensburg, Germany, 4 Henry Ford Hospital, Detroit, MI, USA, 5 EPI-Q Inc, Oak Brook, IL, USA, 6 HealthCore, Inc., Wilmington, PA, USA, 7 St. Luke's Hospital, Chesterfield, MO, USA, 8 Clinilabs, Inc., New York, NY, USA OBJECTIVES: To evaluate the reliability and validity of the Brief Insomnia Questionnaire (BIQ), a fully-structured measure to assess insomnia based on DSM-IV-TR, ICD-10, and RDC criteria. METHODS: The AIS is a large (n = 10,094) epidemiological survey of the prevalence and correlates of insomnia in a nationally representative sample of managed health care plan subscribers. Probability sub-samples of AIS respondents over-sampling BIQ cases completed either short-term test-retest interviews (n = 59) or clinical reappraisal interviews (n = 203) to assess BIQ reliability and validity. RESULTS: Test-retest correlations were .72-.95 for reports of frequency and .47-.94 for reports of severity of sleep problems (initiation, maintenance, non-restorative sleep), .66-.88 for reports of daytime impairment/distress, and .62 for reported duration. Good individual-level concordance was found between diagnoses based on the BIQ and clinical interviews for meeting criteria in any of the three diagnostic systems, with area under the receiver operating characteristic curve (AUC, a measure of classification accuracy not influenced by disorder prevalence) of .86 for dichotomous classifications. AUC increased to .94 when symptom-level data were added to generate a continuous measure of predicted probability of clinical diagnosis. AUC was lower for dichotomous classifications based on RDC (.68) and ICD-10 (.70) than DSM-IV-TR (.83) criteria, but increased when symptom-level data were added to generate continuous measures of predicted probability of diagnoses (.92-.95). CON-CLUSIONS: The results demonstrate that the BIQ can be used to obtain accurate estimates of prevalence and correlates of insomnia in the American Insomnia Survey.
PND24 EVALUATING THE IMPACT OF RESTLESS LEGS SYNDROME (RLS) ON NEXT DAY FUNCTIONING
Abraham L 1 , Lasch KE 2 , Patrick J 3 , Piault E 2 , Tully SE 2 , Treglia M 4 1 Pfizer Ltd, Sandwich, UK, 2 Mapi Values, Boston, MA, USA, 3 Pfizer, Inc., New London, CT, USA, 4 Pfizer Inc, New London, CT, USA OBJECTIVES: Symptoms of Restless Legs Syndrome (RLS) typically worsen in the early evening and nighttime affecting patients' quality and duration of sleep which can have next day sequelae detrimental to daytime performance. The present qualitative research aimed to support the content validity of a new self-reported outcome measure to document the impact of disturbed sleep due to RLS on next day functioning. METHODS: An initial conceptual framework was developed based upon a review of the literature. The development of the Restless Legs Syndrome-Next Day Impact (RLS-NDI) questionnaire included: concept elicitation interviews with 20 clinicianconfirmed idiopathic RLS patients in the US (aged 35-64); grounded theory data collection and analysis methods; achievement of saturation; and review by clinical and measurement experts to generate items, responses, and instructions for the new scale. Cognitive interviews were conducted with an additional 15 idiopathic RLS patients (aged 25-68) to ensure understanding of the new measure, concept comprehensiveness, and to identify any necessary revisions to the items and conceptual framework. RESULTS: Twenty-three items were generated from patient quotes obtained during the concept elicitation interviews. Impacts on next day functioning spontaneously attributed to disturbed sleep due to RLS symptoms included: activities of daily living (i.e., work, household chores), cognitive functioning (i.e., concentration, forgetfulness, mental tiredness, alertness), emotional functioning (i.e., irritability, depressed mood), physical functioning (i.e., physical tiredness, active leisure activities), energy, daytime sleepiness, and social functioning (i.e., relationships, social activities/situations). Concept saturation was achieved. Modifications to questions and responses were based on feedback provided during cognitive interviews. The final measure consists of 14 items assessed "today" and rated on a severity numeric rating scale. CONCLU-SIONS: The RLS-NDI is an evaluative tool with demonstrated content validity to assess the impact of disturbed sleep due to RLS symptoms on RLS patients' next day functioning.
PND25 REFINING THE MEASUREMENT OF MOTOR AND NON-MOTOR SYMPTOMS IN PARKINSON'S DISEASE PATIENTS WITH FLUCTUATING SYMPTOMS
Buck PO 1 , White MK 2 , Castelli-Haley J 1 , Rendas-Baum R 3 1 Teva Neuroscience, Kansas City, MO, USA, 2 QualityMetric Incorporated, Lincoln, RI, USA, 3 QualityMetric Health Outcomes Solutions, Lincoln, RI, USA OBJECTIVES: Parkinson's disease (PD) is the second most prevalent neurodegenerative disorder in the US. The Scales for Outcomes in Patients with Parkinson's disease Diary Card (SCOPA-DC) is a daily diary designed to measure motor impairment in PD patients with fluctuating symptoms. Consistent with the FDA's final guidance on patient-reported outcome measures, this study aimed to evaluate the content validity of the SCOPA-DC in the US and determine the feasibility of adding items that measure non-motor symptoms using qualitative techniques. METHODS: A literature review identified the most dominant non-motor symptoms experienced by PD patients with fluctuating symptoms. Three focus groups were conducted with PD patients (n = 24) to identify themes that specifically addressed the study objectives. The original SCOPA-DC was modified based on findings from the literature review and patient input. A fourth focus group (n = 9) consisted of a cognitive debriefing of the revised SCOPA-DC that included additional items and modified structure based upon the previous results. RESULTS: Findings from the focus groups demonstrated support for the content of the original SCOPA-DC, generally finding it to be clear and intuitive, despite difficulties with some item definitions, time frames, and response labels. With respect to non-motor symptoms, seven domains were consistently mentioned: fatigue, concentration/memory, anxiety, pain, difficulty swallowing, frequent urination, and sweating. The cognitive debriefing focus group reported that the revised SCOPA-DC format was easier to use, provided better focus on the items and time frames, and more adequately captured experiences throughout the day as compared to the original. CONCLUSIONS: Non-motor symptoms occur frequently in PD patients with fluctuating symptoms and have a significant impact on health-related quality of life. A reliable and validated patient-reported daily diary may improve the ability to describe PD progression by accurately measuring both motor and non-motor symptoms. Additional quantitative research is needed to evaluate the psychometric properties of the revised SCOPA-DC.
PND26 VALIDATING USE OF THE MIGRAINE-SPECIFIC QUALITY OF LIFE QUESTIONNAIRE VERSION 2.1 (MSQ) ACROSS MIGRAINE DISORDERS
Elson CL 1 , Maglinte GA 2 , Rendas-Baum R 3 , DeRosa M 3 , Yang M 3 , Varon SF 2 1 University of Georgia, Athens, GA, USA, 2 Allergan, Inc, Irvine, CA, USA, 3 QualityMetric Incorporated, Lincoln, RI, USA OBJECTIVES: To provide evidence for the reliability and validity of the Migraine-Specific Quality of Life Questionnaire Version 2.1 (MSQ) for use across migraine disorders. METHODS: Cross-sectional data were collected via web-based survey in nine countries/regions. Participants were classified per ICHD-2 criteria as having chronic migraine (CM, ≥15 headache days/month), high-frequency episodic migraine (HEM, 10-14 headache days/month), or low-frequency episodic migraine (LEM, ≤9 headache days/month). Three MSQ domains Role Function-Preventive (RP), Role Function-Restrictive (RR), and Emotional Function (EF) were rescaled to 0-100, where higher scores indicate better health-related quality of life (HRQOL), and analyzed for internal consistency reliability (Cronbach's alpha), construct validity (correlations assessed between MSQ scales and measures of depression/anxiety [Patient Health Questionnaire; PHQ-4], disability [Migraine Disability Assessment Questionnaire; MIDAS], and functional impact [Headache Impact Test; HIT-6], where lower scores indicate better HRQOL for each), as well as discriminant validity across migraine groups. RESULTS: A total of 8726 eligible respondents were classified as follows: 5.7% CM (n = 499), 5.9% HEM (n = 515), and 88.4% LEM (n = 7,712). Migraineurs were mostly female (83.5%) with a mean (±SD) age of 40.3 ± 11.4, similar across the groups. MSQ domain scores for CM, HEM, and LEM groups respectively were: RP = 61.4 ± 26.1, 65.9 ± 23.8, and 72.1 ± 23.9; RR = 44.4 ± 22.1, 48.3 ± 22.8, and 57.0 ± 24.1; EF = 48.3 ± 28.1, 57.8 ± 27.7, and 67.8 ± 26.5. Internal consistency of the total sample for RP, RR, and EF was 0.90, 0.96, and 0.87, respectively. Similar values were observed across migraine groups. Varied by domains and migraine groups, MSQ scores correlated moderately to highly with scores from the PHQ-4 (r = −0.28 to −0.47), MIDAS (r = −0.42 to −0.58), and HIT-6 (r = −0.55 to −0.71). Known groups validity indicated significant differences (p < 0.0001) in the hypothesized direction between CM, HEM, and LEM for RP (F = 58.74), RR (F = 91.78), and EF (F = 153.38). CONCLUSIONS: The MSQ is a reliable and valid questionnaire that can differentiate the functional impact between CM, HEM, and LEM.
PND27 CONFIRMATORY FACTOR ANALYSIS AND DIFFERENTIAL ITEM FUNCTIONING ANALYSIS OF THE MIGRAINE-SPECIFIC QUALITY OF LIFE QUESTIONNAIRE VERSION 2.1 IN CHRONIC MIGRAINEURS
Rendas-Baum R 1 , Maglinte GA 2 , DeRosa M 1 , Yang M 1 , Varon SF 2 1 QualityMetric Incorporated, Lincoln, RI, USA, 2 Allergan, Inc, Irvine, CA, USA OBJECTIVES: The Migraine-Specific Quality of Life Questionnaire Version 2.1 (MSQ) is a 14-item health-related quality of life instrument that measures the functional impact of migraine across three domains: Role Function-Preventive (RP), Role Function-Restrictive (RR), and Emotional Function (EF). This study evaluated the factor structure and cross-cultural comparability of the MSQ in Chronic Migraine (CM) sufferers. METHODS: Cross-sectional data were collected via web-based survey, across eight countries. Respondents were classified as having CM per ICHD-2 criteria with ≥15 headache days/month (n = 499). Confirmatory factor analysis (CFA) of the 3-factor model was conducted using the robust maximum likelihood estimator (MLR) assuming multivariate normality. Goodness-of-fit was assessed by the comparative fit index (CFI), Tucker-Lewis Index (TFI), and root mean square error of approximation (RSMEA). Differential item functioning (DIF) was tested using ordinal logistic regression of MSQ item scores on group membership and trait level explanatory variables. Groups were based on country (Australia, Canada, Germany, Spain, France, Great Britain, Italy, United States) and language (English/non-English). Nonuniform DIF (significant interaction term between group membership and trait level, p < 0.05) and uniform DIF (>10% change in the trait level coefficient resulting from removal of the group membership term from the model) were identified. RESULTS:
The 3-factor model demonstrated good fit (CFI = 0.97; TFI = 0.96; RMSEA = 0.07) among CM sufferers. Factor loadings ranged between 0.72 and 0.89, and had similar values across the three factors. Most MSQ items showed absence of DIF. Non-uniform country DIF was identified in items 5 (inability to concentrate; p = 0.028) and 12 (fed up or frustrated; p = 0.037). Item 12 also presented non-uniform DIF related to language (p = 0.010). CONCLUSIONS: Among Chronic Migraineurs, the MSQ provides a valid measure of RP, RR, and EF, yielding domain scores that can be reliably compared across languages and countries. International, London, London, UK OBJECTIVES: Increasingly health status measures, used to measure the subjective functioning and well being of respondents, are being used in trials of treatments which are undertaken in a variety of countries. The purpose of this study was to evaluate the psychometric properties of a short form health survey, the Parkinson's Disease Questionnaire (PDQ-8), cross-culturally, by comparing results gained from this instrument to the original longer form instrument-the PDQ-39. METHODS: Data are from the Global Parkinson's Disease Survey (GPDS) a cross national survey which utilised the thirty nine item Parkinson's Disease Questionnaire (PDQ-39) as a major outcome measure. In this study, we evaluate results from the PDQ-8 (Single Index Score PDQ-8-SI) with results from the parent form (from which the PDQ-8 was derived), of the instrument in the USA, Canada, Spain, Italy and Japan. RESULTS: We evaluate response rate (97% of the 819 respondents completed all items on PDQ-8), data quality, score reliability (internal reliability of the eight items of the PDQ-8 was calculated for all countries using Cronbach's alpha, USA = 0.88; Canada = 0.83; Italy = 0.87; Spain = 0.79 and Japan = 0.73) and scaling assumptions of the instrument in the USA, Canada, Spain, Italy and Japan. CONCLUSIONS: The evidence suggests that PDQ-8-SI seems a useful measure in studies where a short measure, providing an overall index of self perceived health in PD, is required. The PDQ-8 is a practical and informative instrument for the evaluation of overall quality of life of PD patients in cross-cultural studies.
